Rethinking Clinical Trials

MARCH 6, 2024

Payers should have some incentive to improve outcomes because sustained reduction in HbA1c from poor to fair can result in cost savings. The average duration of the intervention was 1 year, and the cost was about $2,000 per participant. The study found a null effect on HbA1c. 9% of the U.S. Learn more Read more in JAMA.

Clinical Trials 141

Clinical Trials Clinical Trials Medicine Trials 141

STAT News

MARCH 10, 2023

Enjoy, and see you soon … By law, Medicare will have to take a medication’s efficacy and its research and development costs into account when it starts to negotiate drug prices — but recent research shows pharma companies ignore those factors when they pick prices for their products , STAT explains. Two

Insulin 96

Insulin Pharmacy Pharma Companies Drugs 96

Rethinking Clinical Trials

NOVEMBER 21, 2023

The second aim was to conduct a pilot intervention to demonstrate feasibility of delivering the intervention and preliminary effects in a 3 healthcare systems. Text messages can be implemented as a low-cost intervention to improve medication refill adherence across different healthcare systems with disperate EHR systems.

Clinical Trials 141

Clinical Trials Clinical Trials Trials Development 141

Rethinking Clinical Trials

JULY 14, 2023

GGC4H chose a parent-focused prevention and health promotion because stronger bonds with family results in better health and educational outcomes, and they are cost effective. Discussion Themes -How do you most effectively move this toward adoption? I was surprised and pleased by how well the virtual adaption went.

Clinical Trials 130

Clinical Trials Clinical Trials Trials Research 130

Rethinking Clinical Trials

MAY 25, 2023

Aspirin is now the most commonly used VTE prophylaxis for Arthroplasty patients, in which Aspirin and LMWH are both safe and effective prophylaxis options. Researchers aimed to test the safety and effectiveness of Aspirin use as prophylaxis in orthopedic trauma cases.

Trials 130

Trials Clinical Trials Clinical Trials Compliance 130

pharmaphorum

NOVEMBER 19, 2021

The cost-effectiveness agency had turned down Evrysdi (risdiplam) in draft guidance published in June, saying it was too expensive, but after negotiations with Roche has reached a deal that will make the drug available to around 1,500 people in England.

Drugs 98

Drugs Gene Therapy Genetic Disease Gene 98

STAT News

OCTOBER 6, 2022

million tag as cost effective for a Bluebird Bio drug called Zynteglo for the blood disorder beta thalassemia, Arbuckle said in an interview.  Even a drug-price watchdog, the Institute for Clinical and Economic Review, deemed the $2.8

Gene Therapy 98

Gene Therapy Gene Insulin Drugs 98

Pharmaceutical Technology

JANUARY 17, 2023

Despite its high price tag, bimagrumab’s unique features set it apart from currently marketed therapies. On January 12, Versanis Bio announced that enrollment had begun for its Phase IIb trial, BELIEVE (NCT05616013), which aims to study bimagrumab’s (BYM-338) efficacy and safety in the US, among other locations.

Development 130

Development Compliance Trials Marketing 130

Pharmaceutical Technology

MAY 1, 2023

CTH-004 is developed by genetically altering patient T cells for inserting a chimeric antigen receptor (CAR) to target a marker (TAG-72) on ovarian cancer cells and delete genes which are involved in T cell function suppression. Shunxi will also hold an option to negotiate rights to other CAR-T products, which include the licenced IP.

Gene Therapy 130

Gene Therapy Gene Development Clinical Trials 130

Drug Discovery World

JANUARY 30, 2024

He said: “Increasing the level of automation and standardisation is not only the way to reduce manufacturing costs, but also paves the way for follow-on approvals once a platform technology is part of an approval.  She said: “Payment options will be devised to absorb the costs. One

Gene Therapy 71

Gene Therapy Manufacturing Gene Clinical Trials 71

Scienmag

SEPTEMBER 9, 2020

Massive price tag of COVID-19 response in 73 low- and middle-income countries underscores benefits of investing in pandemic preparedness New modelling research, published in The Lancet Global Health journal, estimates that it could cost low- and middle-income countries (LMICs) around US$52 billion (equivalent to US$8.60

Research 40

Research Development Medicine 40

XTalks

MARCH 25, 2024

Related: Why the UK is Facing a Tomato Shortage in 2023 Chocolate Makers Feel the Pinch With the likelihood of a fourth consecutive poor growing season, chocolate manufacturers like Hershey and Mondelez (owners of Cadbury) are forced to raise prices to offset the rising cost of cocoa.

Production 110

Production Manufacturing Branding Marketing 110

XTalks

JUNE 28, 2023

The approval is restricted to ambulatory patients within this narrow age range due to uncertainty around its effectiveness in older children, which Sarepta hopes to clarify in a confirmatory trial. million price tag of Elevidys, a one-time gene therapy. He said an analysis suggested that the drug could be cost-effective at $5 million.

Gene Therapy 98

Gene Therapy Gene Protein FDA Approval 98

Pharmaceutical Technology

JULY 14, 2022

Due to the high price tags associated with these speciality medicines, innovators have naturally favoured big markets with high GDP such as the US and EU-5 (Germany, France, Spain, Italy, and the UK). “The Go-to-market strategies. The choice of where to launch an orphan drug is an important and difficult decision.

Drugs 147

Drugs Medicine Marketing Development 147

pharmaphorum

APRIL 14, 2022

US cost-effectiveness watchdog ICER has handed bluebird bio some good news ahead of its FDA advisory committee meeting for rare blood disorder gene therapy beti-cel in June, by endorsing its proposed $2.1 million price tag. gene therapy is cost-effective appeared first on.

Gene Therapy 63

Gene Therapy Gene Marketing Clinical Trials 63

Roots Analysis

MARCH 1, 2024

In order to effectively combat the problems related to counterfeit medicines, several companies have come up with innovative technologies to provide the necessary tools to manufacturers, healthcare professionals and patients to authenticate pharmaceutical products. Such technologies have been shown to have highly secured features.

Packaging 52

Packaging Packaging Production Manufacturing 52

Rethinking Clinical Trials

SEPTEMBER 21, 2023

Behavioral nudges may increase healthy food purchasing by “nudging” consumers to purchase healthier options by providing discounts or lower-cost options. Providing default options is also an effective strategy in motivating individuals to purchase fruits and vegetables.

Clinical Trials 130

Clinical Trials Clinical Trials Sales Trials 130

Drug Discovery World

MAY 22, 2023

The cost 2022 has not been shy of approvals – Uniqure and CSL’s Haemophilia B drug even nabbed the title of “Most Expensive Drug” at $3.5 But are these price tags a barrier to access? This tracks with a similar lack of public, medical and government knowledge about the availability, progress, and effectiveness of CGTs.

Gene Therapy 52

Gene Therapy Gene Drugs Contamination 52

Rethinking Clinical Trials

OCTOBER 11, 2023

Examples of implementation measures include acceptability, adoption, appropriateness, affordability, cost, feasibility, fidelity, reach, etc. An implementation study generally is used when you have an intervention that has already been shown to be effective on health outcomes, so it’s less important to be concerned about that.

Clinical Trials 152

Clinical Trials Clinical Trials Trials Research 152

pharmaphorum

NOVEMBER 16, 2021

The cost-effectiveness agency has backed Ontozry (cenobamate) as an option for treating focal onset seizures with or without secondary generalised seizures in adults with drug-resistant epilepsy that has not been adequately controlled with at least two prior antiseizure medicines.

Drugs 98

Drugs Medicine Clinical Trials Clinical Trials 98

World of DTC Marketing

DECEMBER 13, 2021

billion included out-of-pocket costs of $16.22 billion and patient time costs of $4.87 As cancer survival rates rise, so do the price tags of life-saving treatments. Monthly drugs costs may reach $100,000, causing many Americans to struggle with the physical and emotional effects of high out-of-pocket medical costs.

Drugs 55

Drugs FDA Approval Medicine Containment 55

pharmaphorum

DECEMBER 23, 2022

But along with strong efficacy come some considerable risks and costs: cytokine release syndrome (CRS), where a patient’s immune system becomes dangerously over-stimulated, and neurotoxicity are potential side effects that need to be managed. Side effects and cost implications.

Development 52

Development Drugs Clinical Development Antibody 52

pharmaphorum

JUNE 8, 2021

” Biogen meanwhile has been taking flak over its decision to price Aduhelm at $56,000 per year, which looks set to re-ignite debate in the US about the cost of medicines. Meanwhile, side effects such as amyloid-related imaging abnormalities (ARIAs) could also be a barrier to uptake, according to managing analyst Alessio Brunello.

Drugs 98

Drugs Marketing FDA Approval Trials 98

XTalks

DECEMBER 13, 2023

Related: Roctavian Becomes First Gene Therapy for Severe Hemophilia A to Get FDA Nod Casgevy and Lyfgenia Pricing and Warnings The price tags of both gene therapies are steep, given the complexity of developing gene therapies and as therapies meant to be one-time treatments. Vertex-CRISPR’s Casgevy has a US list price of $2.2

Gene Therapy 98

Gene Therapy FDA Approval Gene In-Vivo 98

XTalks

APRIL 18, 2024

The disease has an estimated $360 billion cost to the US economy. The approval of amyloid-beta-targeting therapies like Leqembi and recently discontinued Aduhelm (aducanumab) have come with controversy around their clinical effectiveness. However, the guidance doesn’t say whether it could serve as a study’s primary endpoint on its own.

Clinical Trials 52

Clinical Trials Clinical Trials In-Vitro Protein 52

pharmaphorum

NOVEMBER 24, 2022

One issue has been the cost of the drug, with health technology assessment agency NICE in the UK and the ICER organisation in the US both concluding its price tag means it is not a cost-effective option for health systems.

Trials 52

Trials Sales Drugs Marketing 52

Rethinking Clinical Trials

NOVEMBER 21, 2022

The FIRST-ABC trial adopted a pragmatic design with a heterogenous patient cohort where the indication to start NRS was based on physiological criteria, which allowed the results to be applicable to all situations where HFNC is started. Many other trials in the country were behind and everyone else had to stop. pctGR, @Collaboratory1.

Trials 130

Trials Clinical Trials Clinical Trials Packaging 130

pharmaphorum

APRIL 20, 2021

The cost-effectiveness agency has said that anti-CD20 antibody Kesimpta (ofatumumab) can be prescribed via the NHS in England and Wales as a treatment for adults with RMS with active disease, as either a first-line therapy or after alternative drugs have been tried.

Sales 110

Sales Medicine Drugs Marketing 110

pharmaphorum

AUGUST 18, 2022

bluebird has opted to launch it at a cost of $2.8 million price tag attached to the therapy when it was first made available in Europe, and is also well above the proposed $2.1 million level that cost-effectiveness organisation ICER said would be acceptable in a July report. million, which compares to the $1.7

Gene Therapy 52

Gene Therapy FDA Approval Gene Clinical Trials 52

pharmaphorum

JUNE 2, 2022

There are approximately 7,000 rare diseases and only 5% of these have an effective treatment. And of course, in many cases, these drugs have higher than average price tags compared to the wider market which is due to the limited – or in most cases – non-existent competition within a treatment area.”. It is estimated that between 3.5

Drugs 52

Drugs Sales Marketing Development 52

pharmaphorum

AUGUST 21, 2022

There’s no word yet on its pricing, but for comparison Spravato was launched with an annual price tag of around $32,400, which the Institute for Clinical and Economic Review (ICER) concluded was around 25% to 52% too high to be cost effective.

Drugs 98

Drugs FDA Approval Production Marketing 98

pharmaphorum

JUNE 2, 2021

The cost-effectiveness agency’s initial assessment is that Evrysdi is simply too expensive at its current price to be provided to the roughly 1,500 people with the rare genetic disorder who might be eligible to receive it. . — Spinal Muscular Atrophy UK (@SMA_UK_) June 2, 2021.

Gene Therapy 52

Gene Therapy Gene Drugs Medicine 52

Rethinking Clinical Trials

AUGUST 28, 2023

Time, cost and failure to recruit trial participants are significant barriers that must be addressed. It would be such a waste of valuable data, valuable approaches, and valuable infrastructure to not embed clinical trials effectively into health care systems. We see that as an important part of the future.

Clinical Trials 130

Clinical Trials Clinical Trials Trials Development 130

Rethinking Clinical Trials

AUGUST 28, 2023

Time, cost and failure to recruit trial participants are significant barriers that must be addressed. It would be such a waste of valuable data, valuable approaches, and valuable infrastructure to not embed clinical trials effectively into health care systems. We see that as an important part of the future.

Clinical Trials 130

Clinical Trials Clinical Trials Trials Development 130

pharmaphorum

JUNE 12, 2022

Beti-cel has already been approved for marketing in Europe as Zynteglo, with a price tag of around $1.8 In April, influential US cost-effectiveness watchdog ICER endorsed beti-cel’s proposed $2.1 million price tag, saying its ability to help patients reach sustained transfusion independence justified its high price.

Gene Therapy 58

Gene Therapy Gene Marketing Trials 58

XTalks

FEBRUARY 27, 2024

Amtagvi Price Following the approval, Vogt revealed on a call that Amtagvi will be priced at a wholesale acquisition cost of $515,000 per patient. The cost is the highest of any cell-based cancer drug in the US. Most chimeric antigen receptor (CAR)-T cell therapies cost around $500,000 or less.

FDA Approval 52

FDA Approval Manufacturing In-Vivo Trials 52

XTalks

JANUARY 28, 2022

Kimmtrak has a price tag of $18,760 per vial, which amounts to a weekly dose. months), so the average cost per patient will be approximately $400,000. The company is expecting approval from the European Medicines Agency (EMA) soon as it prepares for a European launch in the second quarter of this year.

FDA Approval 98

FDA Approval Development Licensing Licensing 98